Murat TUNÇ, Harun YÜKSEL, Elif ÖNDER, Murat KAYA, Halil İbrahim ONDER

Retina Ven Dal Tıkanıklığı Geçiren Hipertansif ve Diyabetik Olgularda Aspirin Kullanımı

Amaç: Retina ven dal tıkanıklığı (RVDT) geçiren hipertansiyonu ve diyabeti olan olgulardaAspirin kullanımının bir risk faktörü olup olmadığını araştırmak amaçlanmıştır.Gereç ve Yöntem: Çalışmaya RVDT geçiren 30 hipertansif olgu dahil edilmiştir. Bu olgulardanAspirin kullanan ve kullanmayanlar görme düzeyi, retina kanamalarının genişliği, maküla ödemive retinada yeni damar oluşumu yönünden irdelenmiştir.Bulgular: Çalışmaya alınan 30 olgudan 18'i Aspirin kullanmıyordu 12'si ise Aspirinkullanıyordu. Aspirin kullanmayan 18 olgudan 10'unda görme düzeyi 0.1'in altındaydı. Aspirinkullanan 12 olgudan 3'ünde görme 0.1 ve alında saptandı. (p=0.09) Aspirin kullanan olgulardahemoraji yaygınlığı ile görme düzeyi arasında bir korelasyon saptanmadı.Sonuç: Düzgün kan basıncı kontrolü sağlanan diyabetik olgularda Aspirin kullanımı görselprognozu olumlu etkileyebilir

Anahtar Kelimeler:

Aspirin, Retinal ven dal tıkanıklığı, Hipertansiyon

Aspirin Use in Branch Retinal Vein Occlusion in Diabetic and Hypertensive Patients

Purpose: The aim was to investigate whether aspirin use is a risk factor in Branch retinal veinocclusion in hypertensive and diabetic patients.Materials and Methods: The study included 30 hypertensive patients who were diagnosedbranch retinal vein occlusion. Visual acuity, width of retinal hemorrhages, macular edema andretinal neovascularization were compared between aspirin using and non-using patients.Results: Of the 30 cases, 18 were using aspirin, 12 were not. Visual acuity less than 0.1 wasobserved in 10 of 18 aspirin using patients and 3 of 12 non-using patients (p = 0.09). There wasno correlation between visual acuity and wide of retinal hemorrhage.Conclusion: The use of aspirin in patients with well controlled hypertension and diabetes maypositively effect the visual outcome

Keywords:

Aspirin, Branch retinal vein occlusion, Hypertension,

PDF

___

Rogers S, McIntosh RL, Cheung N, et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313– 319.e1.

Cheung N, Klein R, Wang JJ, et al Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multi-ethic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008;49:4297–302.

Sanborn GE. Venous occlusive disease of retina. In: Tasman W, Jaeger E, eds. Duane’s Clinical Ophthalmology. Chapter 15. Philadelphia: Lippincott. Revision; 1996: 3.

Liesegang TJ, Deutsch TA, Grand MG. Retinal Vascular Disease, in Basic and Clinical Science Course. Section 12; Chapter 5. San Francisco: Foundation of the American Academy of Ophthalmology. 2001 – 2002: 127 – 131.

Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med 2010;363:2135–2144.

Turello M, Pasca S, Daminato R, et al. Retinal vein occlusion: evaluation of ‘classic’ and ‘emerging’ risk factors and treatment. J Thromb Thrombolysis 2010; 29:459–464.

Battaglia Parodi M, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophtalmologica 2009;223:298– 305.

Wong TY, Larsen EKM, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities and Cardiovascular Health Studies. Ophthalmology 2005;112:540–547.

Figueroa MS, Torres R, Alvarez MT. Comparative study of vitrectomy with and without vein decompression for branch retinal vein occlusion: a pilot study. Eur J Ophthalmol. 2004; 14: 40 – 47.

Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent-onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000; 84: 609 – 613.

Achenbach LO, Weller-Mann G .Visual outcome after treatment with low-dose taps. Ophthalmologica. 1999; 213: 360 – 366.

Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999; 30: 427 – 434.

Vannas S, Orma H. Experience of treating retinal venous occlusion with anticoagulant and antisclerosis therapy. Arch Ophthalmol. 1957; 58: 812 – 828.

The Branch Retinal Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984; 98: 271 – 282.

Senen K, Topal E, Kilinc E, et al. Plasma viscosity and mean platelet volume in patients undergoing coronary angiography. Clin Hemorheol Microcirc. 2010;44:35–41.

Leoncini G, Signorello MG, Segantin A, et al. In retinal vein occlusion platelet response to thrombin is increased. Thrombosis Research 2009;124e48–e55.

Dodson PM, Westwick J, Marks G, Kakkar VV, Galton DJ. Beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 1983;67:143–146.

Leoncini G, Bruzzese D, Signorello MG, et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007;97:218–227.

Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001;22:1561-1571.

Liew G, Mitchell P, Leeder SR, Smith W, Wong TY, Wang JJ. Regular aspirin use and retinal microvascular signs: the Blue Mountains Eye Study. J Hypertens. 2006 Jul;24(7):1329 35.

Early Treatment Diabetic Retinopathy Study Research Group : Effect of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology, 1991; 98: 757-765.

The DAMAD Study Group : Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical tral. Diabetes, 1989; 38: 491-498.

Handin RA, Anticoagulant, fibrinolytic, and antiplatelet therapy. In: Braunward E, Fausi AS, eds. Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001: 758 – 760.

Harker LA. Antithrombotic therapy. In: Bennet JC, Plum F, eds. Cecil Textbook of Medicine. 21th ed. Philadelphia: Saunders; 2000: 119 – 122.